Provider review · Public records checked September 27, 2026
Noom sema microdose review: the program, the supply period and the refund stage
Identify which Noom program is being described before applying its price, subscription period, pharmacy statement or cancellation policy.
Editorial document research. No clinician review or firsthand treatment experience claimed.
The word month can make unlike offers appear alike. A program may collect one charge for a subscription period while describing a different period of medication supply. Noom's Microdose offer makes that distinction explicit in its footnote. Understanding it does not require medication arithmetic; it requires keeping the agreement's time period separate from the instructions for the supplied medicine.
This article is published by Plain Dose Language, part of CoreAge Rx's promotional network. CoreAge receives a disclosed commercial first position; competitor coverage is not an independent clinical ranking. Our September 27, 2026 review examines Noom's official offer and support documents. It includes no patient experience, subscription transaction or assessment of a particular prescription.
Start with the full program name and medicine
The Microdose GLP-1Rx page names compounded semaglutide and tirzepatide options. Noom also advertises other programs, including branded-medication telehealth and a separate proactive-health offering. Sharing a company name does not make their medicines, charges or included services identical.
For a semaglutide discussion, the record needs to identify that ingredient and the selected program rather than assume every GLP-1 claim applies. The offer-record comparison distinguishes that identification step from choosing a treatment. Noom states that prescribing depends on clinical appropriateness and availability is not universal across states. This review does not determine either for an individual.
The introductory subscription and medicine periods differ
The Microdose offer describes a starting $79 charge, plus tax, for an initial three-week subscription and four weeks of medication. The later offer uses $179 per month plus tax for a twelve-week subscription, subject to program selection. These are the provider's commercial period descriptions, not directions for the amount or frequency of a patient's treatment.
The cost article updated September 22 further identifies semaglutide's continuation as $537 every twelve weeks. Our monthly-price guide explains why that charge should not be silently rewritten as a freely cancellable monthly payment. A rate used in an advertisement and a scheduled debit need not be the same number.
A directory and an individual quote have different jobs
The current pricing directory displays both $79 and $49 introductory figures for Microdose. It also distinguishes medication-inclusive bundles from telehealth for branded medicines, where medication costs are separate. Those displays are useful for identifying the questions, but they do not verify which promotion or total would apply to a particular person.
A complete quote should identify the selected program, medicine, initial charge, renewal charge and included services together. Noom's public page describes clinical care and behavioral support alongside medication when prescribed. This article has not established the terms of a personal offer, tax treatment, insurance coverage or the conditions of a promotion by entering checkout.
The refund policy is specific to the program and clinical stage
Noom's refund policy distinguishes several products. For Noom Med programs with medication included, it states that refunds are unavailable once a prescription has been written. The branded-medication telehealth policy instead uses a completed clinical visit as a relevant boundary. The separate Noom Weight policy should not be borrowed as though every medication plan shares its initial refund window.
These are published policy distinctions, not a finding about a disputed individual charge. They also show why refund timing cannot be inferred from whether a parcel has arrived. The relevant service event may occur before shipment, and a reviewer should not invent a refund guarantee from a general cancellation headline.
Ending renewal does not necessarily cancel every pending refill
The Noom Med support article says cancelling sets the subscription to expire and separately directs members with unwanted upcoming refills within the current subscription to support. That wording distinguishes future subscription renewal from an order already associated with the current period. We did not test either administrative process.
FTC guidance emphasizes understanding renewal and cancellation terms and retaining records. It does not decide an individual Noom refund request. Nor does an administrative step replace clinical advice about a prescribed medicine. The review provides no discontinuation schedule, workaround or recommendation to change treatment because a billing period has changed.
A registered facility is not approval of the compound
The offer describes production in an FDA-registered facility while acknowledging that the compound has not been reviewed by FDA for safety, efficacy or quality. FDA's explanation supports keeping those concepts distinct. Facility wording cannot be substituted for an approved finished-product record or a personal pharmacy label.
The current Wegovy prescribing information documents specific approved presentations and uses. It should not be treated as instructions for a Noom-supplied compound. The device guide and terminology guide explain why the exact presentation matters, without transferring device directions, measurements or conversion examples between products.
A well-described bundle still needs clinical accountability
Noom's offer describes ongoing clinical access, coaching and personalized care. Those services do not establish that a particular reader will benefit, that a lower amount removes serious risks, or that each favorable outcome belongs to the medication alone. The approved-product label retains important warnings and contraindications that provide context for professional discussion.
Our lower-amount safety guide keeps those limits visible alongside the commercial terms. The CoreAge review applies the same approach to this publication's featured provider. A useful conclusion identifies the relevant medicine and agreement, clarifies who answers each question, and leaves prescribing decisions with the clinical team rather than the price comparison.
Sources for this article
- Noom: Microdose GLP-1Rx offer ↗Provider program and pricing description · Checked 2026-09-27
- Noom: program cost article, updated September 22, 2026 ↗Provider cost explanation · Checked 2026-09-27
- Noom: Medication Programs and Pricing ↗Provider plan directory · Checked 2026-09-27
- Noom: Refund Policy ↗Provider refund policy · Checked 2026-09-27
- Noom: Med program changes and cancellation ↗Provider subscription and refill information · Checked 2026-09-27
- FTC: Getting In and Out of Free Trials, Auto-Renewals and Negative Option Subscriptions ↗Government consumer information · Checked 2026-09-27
- FDA: Understanding the Risks of Compounded Drugs ↗Regulatory explanation · Checked 2026-09-27
- Wegovy prescribing information, revised June 2026 ↗Current approved-product labeling · Checked 2026-09-27